BRAF and melanoma: In a clinical setting, a combination of the hypomethylating agent decitabine with the BRAF inhibitor vemurafenib was found to be safe and effective in both treatment-naïve and pre-treated BRAF-mutant melanoma patients [105]; a follow-up study evaluating the addition of cobimetinib to this combination was unfortunately terminated due to loss of funding (NCT01876641) (Table 2).